Abstract
Melanoma is one of the most aggressive and therapy-resistant neoplasias. Despite advances achieved through the development of targeted therapies, such as BRAF and MEK inhibitors, and immunotherapies, such as anti-CTLA4 and anti-PD1, which have resulted in increased survival of patients with malignant melanoma, around 50% of these develop resistance to treatments. The characteristic phenot…